Note: Your progress in watching these videos WILL NOT be tracked. These training videos are the same videos you will experience when you take the full ProFirstAid Basic program. You may begin the training for free at any time to start officially tracking your progress toward your certificate of completion.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a major new development in the treatment of severe allergic reactions. For the first time in the UK, a needle-free adrenaline nasal spray has been authorised for emergency use in cases of anaphylaxis — a sudden, severe, and potentially life-threatening allergic reaction.
Until now, adrenaline for anaphylaxis has always been delivered by injection, typically using auto-injectors such as the EpiPen. These devices are highly effective, but for some people — particularly those with a strong fear of needles or who struggle to administer an injection during a crisis — they can present challenges.
The newly approved nasal spray provides a needle-free, single-dose, ready-to-use alternative. Administered through the nostril, the spray delivers adrenaline rapidly into the bloodstream via the nasal mucosa.
The spray is approved for:
The MHRA has emphasised that this new nasal spray does not replace traditional adrenaline auto-injectors. Adrenaline pens remain vital, effective, and life-saving tools. Anyone who currently carries an auto-injector must continue to do so.
Instead, the nasal spray adds an additional safe and effective option — particularly helpful for situations where injections are difficult, delayed, or distressing.
The decision follows a detailed review of clinical evidence showing that the nasal spray delivers adrenaline safely and effectively. This innovation marks an important advancement, making emergency treatment more accessible and user-friendly for people living with severe allergies.
Regardless of the type of adrenaline used, the priorities remain unchanged:
This new needle-free adrenaline spray represents a significant step forward in emergency allergy treatment — offering greater choice, improved accessibility, and a potentially easier way to deliver life-saving care when every second counts.